fbpx
Back to Course

Internal Medicine 101

0% Complete
0/0 Steps
  1. Pneumonia 

    Community-Acquired Pneumonia
    9 Topics
    |
    3 Quizzes
  2. Venous Thromboembolic Disease
    Acute Management of Pulmonary Embolism
    12 Topics
    |
    2 Quizzes
  3. Acute Management of DVT
    10 Topics
    |
    2 Quizzes
  4. Diabetes and Hyperglycemia
    Hyperglycemia in Hospitalized Patients
    11 Topics
    |
    2 Quizzes
  5. Hyperglycemic Crisis: Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome
    13 Topics
    |
    3 Quizzes
  6. Pulmonary Exacerbations
    Chronic Obstructive Pulmonary Disease Exacerbation
    10 Topics
    |
    3 Quizzes
  7. Asthma Exacerbation
    15 Topics
    |
    3 Quizzes

Participants 396

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 3, Topic 4
In Progress

Clinical Presentation

Lesson Progress
0% Complete

Typical signs and symptoms of DVT include:

  • Swelling, pain, warmth, and redness, usually in one leg (may be unilateral or bilateral)
  • Dilated superficial veins over affected area
  • Positive Homan’s sign (pain with dorsiflexion of the foot)
  • Risk factors for DVT include:
    • Older age (>60 years)
    • Obesity
    • Recent surgery or trauma
    • Prolonged immobility
    • Active cancer
    • Estrogen therapy or pregnancy
    • Previous DVT/PE or clotting disorder
    • Indwelling central venous catheter

Special Populations

Several patient populations require special consideration when managing DVT:

  • Pregnancy – VTE risk increases 4- to 5-fold during pregnancy. Low molecular weight heparins (LMWHs) are preferred over warfarin due to lower risks of teratogenicity and bleeding. Monitoring anti-Xa levels is recommended.
  • Cancer – Cancer patients have a 4- to 7-fold higher risk of VTE, especially during chemotherapy. Extended anticoagulation is usually warranted. LMWHs are preferred over warfarin in the initial treatment phase.
  • Renal dysfunction – For CrCl <30 mL/min, unfractionated heparin or LMWH doses may need to be reduced. Direct oral anticoagulants should be avoided or dose reduced depending on the agent.
  • Obesity – Weight-based dosing is preferred for LMWHs. Anti-Xa monitoring can help guide proper dosing. Data for direct oral anticoagulants in morbid obesity is limited.
  • Elderly – Older patients are at increased risk of bleeding on anticoagulants. Close monitoring is warranted. Drug interactions must also be carefully evaluated.

Complications

  • Post-thrombotic syndrome – Venous insufficiency and edema resulting from venous damage. Compression stockings help prevent. Anticoagulation reduces risk.
  • Pulmonary embolism – Potentially fatal complication if large clot breaks off and travels to lungs. Proximal DVTs have higher PE risk. IVCFs may be placed prophylactically.
  • Recurrent DVT – Anticoagulation therapy does not eliminate risk of recurrence, especially when irreversible risk factors are present. Extended treatment duration may be warranted.